Ventyx Biosciences, Inc. ( (VTYX) ) has released its Q4 earnings. Here is a breakdown of the information Ventyx Biosciences, Inc. presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops innovative oral therapies targeting autoimmune, inflammatory, and neurodegenerative diseases, with a focus on NLRP3 inhibitors and treatments for inflammatory bowel disease.